147 related articles for article (PubMed ID: 29763403)
1. Cost of Cancer Drugs: Something Has To Give.
Bender E
Manag Care; 2018 May; 27(5):18-22. PubMed ID: 29763403
[TBL] [Abstract][Full Text] [Related]
2. Are pharmaceuticals cost-effective? A review of the evidence.
Neumann PJ; Sandberg EA; Bell CM; Stone PW; Chapman RH
Health Aff (Millwood); 2000; 19(2):92-109. PubMed ID: 10718025
[TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
4. Drug pricing and value in oncology.
Danzon PM; Taylor E
Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
[TBL] [Abstract][Full Text] [Related]
5. Drug prices. In search of a fix.
Bell H
Minn Med; 2001 Jan; 84(1):24-8, 30-1. PubMed ID: 11202523
[No Abstract] [Full Text] [Related]
6. Cancer drug prices and the free-market forces.
Kantarjian H; Zwelling L
Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
[No Abstract] [Full Text] [Related]
7. Pharmacoeconomics: the new dismal science.
Luchins DJ
Adm Policy Ment Health; 2004 May; 31(5):425-7. PubMed ID: 15379388
[No Abstract] [Full Text] [Related]
8. Market spiral pricing of cancer drugs.
Light DW; Kantarjian H
Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
[No Abstract] [Full Text] [Related]
9. A poke in the pocketbook.
Kiser K
Minn Med; 2012 Aug; 95(8):14-7. PubMed ID: 22953468
[No Abstract] [Full Text] [Related]
10. Clinical research: outlook from industry.
Echols R
Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
[No Abstract] [Full Text] [Related]
11. Will lower drug prices jeopardize drug research? A policy fact sheet.
Light DW; Lexchin J
Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
[No Abstract] [Full Text] [Related]
12. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
13. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical industry.
Lewis L
State Health Care Am; 1994; ():23-7. PubMed ID: 10133845
[TBL] [Abstract][Full Text] [Related]
15. Running short.
Mettner J
Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
[No Abstract] [Full Text] [Related]
16. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
[TBL] [Abstract][Full Text] [Related]
17. Pushback on Zaltrap's price highlights sensitive end-of-life issue.
Dalzell MD
Manag Care; 2012 Dec; 21(12):40-1. PubMed ID: 23304735
[No Abstract] [Full Text] [Related]
18. Just what the HMO ordered: the paradox of increasing drug costs.
Kleinke JD
Health Aff (Millwood); 2000; 19(2):78-91. PubMed ID: 10718024
[TBL] [Abstract][Full Text] [Related]
19. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
Lee J
Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
[No Abstract] [Full Text] [Related]
20. Cancer drugs offer hope, but at huge expense.
Berenson A
N Y Times Web; 2005 Jul; ():A1, C3. PubMed ID: 16075470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
